

Press release
May 4, 2021

Curasight announces appointment of Dr. Kirsten Drejer as new board member

Curasight A/S (“Curasight”) is pleased to add a prominent and experienced biotech profile to its Board of Directors.

Kirsten Drejer holds a PhD in pharmacology and has been involved in drug development throughout her career. She is probably best known as co-founder and CEO of Symphogen A/S for 16 years. During her leadership at Symphogen A/S, she raised more than 300 million EUR from premier international investors, 250 million EUR through partnerships and grew the company to become one of the most successful biotech companies within oncology with more than 100 employees.

Dr. Drejer serves on several boards and holds numerous offices of honor. She was appointed member of the Danish Governments Panel of Entrepreneurs in 2017. She was awarded the ‘BiotechBuilder of the Year’ prize in 2003, ‘Entrepreneur of the Year, Biotech’ in 2007, and portrayed as top women in biotech 2013 by Fierce Biotech.

“It is with great pleasure we welcome Kirsten Drejer as a new member of our Board of Directors. Her vast experience within drug development within oncology, her knowledge on building biotech companies and success in raising capital and closing partnership deals will be of great value to Curasight going forward” says Chairman of the Board of Directors Per Falholt.

An invitation to an extraordinary general meeting on 1 June 2021 in Curasight, to elect Dr. Kirsten Drejer, will be sent no later than 14 days before the extraordinary general meeting.

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO

Phone: +45 22 83 01 60

E-mail: uk@curasight.com

www.curasight.com

Curasight is a clinical development company based in Copenhagen, Denmark. The company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology provides improved diagnosis and risk stratification in multiple cancer types.